Wegovy (semaglutide) is available as an injection, in pre-filled single-dose pens that deliver doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg 1
Significant Weight Reduction: Clinical trials have shown that patients can achieve substantial weight loss, with an average of 15% body weight reduction over 68 weeks
This product is not intended for type 1 diabetes and is not a substitute for insulin when insulin is required
Semaglutide- Picture Courtesy: Mountcastle medical Semaglutide is the drug which is mainly approved for treatment problems related to Type 2 diabetes
Evidence suggests consuming 1.21.6 grams of protein per kilogram of adjusted body weight daily, distributed across 34 meals with approximately 2030 grams per meal
Cost: Injectables used for weight loss are not covered by the Pharmaceutical Benefits Scheme, so patients must pay for these out-of-pocket